Histaminergic Activity in a Rodent Model of Parkinson’s Disease
Rats lesioned shortly after birth with 6-OHDA have been proposed to be a near-ideal model of severe Parkinson’s disease, because of non-lethality of the procedure, near-total destruction of nigrostriatal dopaminergic fibers, and near-total dopamine (DA) denervation of striatum. There are scarce data...
Gespeichert in:
| Veröffentlicht in: | Neurotoxicity research 2009-04, Vol.15 (3), p.246-251 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 251 |
|---|---|
| container_issue | 3 |
| container_start_page | 246 |
| container_title | Neurotoxicity research |
| container_volume | 15 |
| creator | Nowak, Przemysław Noras, Łukasz Jochem, Jerzy Szkilnik, Ryszard Brus, Halina Körőssy, Eva Drab, Jacek Kostrzewa, Richard M. Brus, Ryszard |
| description | Rats lesioned shortly after birth with 6-OHDA have been proposed to be a near-ideal model of severe Parkinson’s disease, because of non-lethality of the procedure, near-total destruction of nigrostriatal dopaminergic fibers, and near-total dopamine (DA) denervation of striatum. There are scarce data that in Parkinson’s disease, activity of the central histaminergic system is increased. Therefore, the aim of this study was to determine histamine content in the brain and the effect of histamine receptor antagonists on behavior of adult rats. At 3 days after birth, Wistar rats were pretreated with desipramine (20.0 mg/kg
ip
) 1 h before bilateral
icv
administration of the catecholaminergic neurotoxin 6-OHDA (67 μg base, on each side) or saline-ascorbic acid (0.1%) vehicle (control). At 8 weeks levels of DA and its metabolites
l
-3,4-dihydroxyphenylalanine (DOPAC) and homovanillic acid (HVA) were estimated in the striatum and frontal cortex by HPCL/ED technique. In the hypothalamus, hippocampus, frontal cortex, and medulla oblongata, the level of histamine was analyzed by immunoenzymatic method. Behavioral observations (locomotion, exploratory-, oral-, and stereotyped-activity) were additionally made on control and 6-OHDA neonatally lesioned rats. Effects of DA receptor agonists (SKF 38393, apomorphine) and histamine receptor antagonists (e.g., S(+)chlorpheniramine, H
1
; cimetidine, H
2
; thioperamide, H
3
agonist) were determined. We confirmed that 6-OHDA significantly reduced contents of DA and its metabolites in the brain in adulthood. Histamine content was significantly increased in the hypothalamus, hipocampus, and medulla oblongata. Moreover, in 6-OHDA-lesioned rats behavioral response was altered mainly by thioperamide (H
3
antagonist). These findings indicate that histamine and the central histaminergic system are altered in the brain of rats lesioned to model Parkinson’s disease, and that histaminergic neurons exert a modulating role in Parkinsonian 6-OHDA-lesioned rats. |
| doi_str_mv | 10.1007/s12640-009-9025-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20172639</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20172639</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-47d5da267e5ece1413c31b08b8273fc747c82290fa2e5ea39bf2cbae4db9c2773</originalsourceid><addsrcrecordid>eNp9kMtKAzEUhoMotlYfwI1k5S6a20wmy1IvFSqK6DpkMpmSOs3UZEboztfw9XwSU6bgztU5cL7_h_MBcE7wFcFYXEdCc44RxhJJTDNEDsCYcJEjllF-mHZMJSo4LUbgJMYVxpRkuTgGIyJZwTMpxmA6d7HTa-dtWDoDp6Zzn67bQuehhi9tZX0HH9NoYFvDZx3enY-t__n6jvDGRaujPQVHtW6iPdvPCXi7u32dzdHi6f5hNl0gwwTvEBdVVmmaC5tZYwknzDBS4qIsqGC1EVyYglKJa00ToZksa2pKbXlVSkOFYBNwOfRuQvvR29iptYvGNo32tu2jopgImjOZQDKAJrQxBlurTXBrHbaKYLXzpgZvKnlTO2-KpMzFvrwv17b6S-xFJYAOQEwnv7RBrdo--PTwP62_NU945w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20172639</pqid></control><display><type>article</type><title>Histaminergic Activity in a Rodent Model of Parkinson’s Disease</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Nowak, Przemysław ; Noras, Łukasz ; Jochem, Jerzy ; Szkilnik, Ryszard ; Brus, Halina ; Körőssy, Eva ; Drab, Jacek ; Kostrzewa, Richard M. ; Brus, Ryszard</creator><creatorcontrib>Nowak, Przemysław ; Noras, Łukasz ; Jochem, Jerzy ; Szkilnik, Ryszard ; Brus, Halina ; Körőssy, Eva ; Drab, Jacek ; Kostrzewa, Richard M. ; Brus, Ryszard</creatorcontrib><description>Rats lesioned shortly after birth with 6-OHDA have been proposed to be a near-ideal model of severe Parkinson’s disease, because of non-lethality of the procedure, near-total destruction of nigrostriatal dopaminergic fibers, and near-total dopamine (DA) denervation of striatum. There are scarce data that in Parkinson’s disease, activity of the central histaminergic system is increased. Therefore, the aim of this study was to determine histamine content in the brain and the effect of histamine receptor antagonists on behavior of adult rats. At 3 days after birth, Wistar rats were pretreated with desipramine (20.0 mg/kg
ip
) 1 h before bilateral
icv
administration of the catecholaminergic neurotoxin 6-OHDA (67 μg base, on each side) or saline-ascorbic acid (0.1%) vehicle (control). At 8 weeks levels of DA and its metabolites
l
-3,4-dihydroxyphenylalanine (DOPAC) and homovanillic acid (HVA) were estimated in the striatum and frontal cortex by HPCL/ED technique. In the hypothalamus, hippocampus, frontal cortex, and medulla oblongata, the level of histamine was analyzed by immunoenzymatic method. Behavioral observations (locomotion, exploratory-, oral-, and stereotyped-activity) were additionally made on control and 6-OHDA neonatally lesioned rats. Effects of DA receptor agonists (SKF 38393, apomorphine) and histamine receptor antagonists (e.g., S(+)chlorpheniramine, H
1
; cimetidine, H
2
; thioperamide, H
3
agonist) were determined. We confirmed that 6-OHDA significantly reduced contents of DA and its metabolites in the brain in adulthood. Histamine content was significantly increased in the hypothalamus, hipocampus, and medulla oblongata. Moreover, in 6-OHDA-lesioned rats behavioral response was altered mainly by thioperamide (H
3
antagonist). These findings indicate that histamine and the central histaminergic system are altered in the brain of rats lesioned to model Parkinson’s disease, and that histaminergic neurons exert a modulating role in Parkinsonian 6-OHDA-lesioned rats.</description><identifier>ISSN: 1029-8428</identifier><identifier>EISSN: 1476-3524</identifier><identifier>DOI: 10.1007/s12640-009-9025-1</identifier><identifier>PMID: 19384597</identifier><language>eng</language><publisher>New York: Springer-Verlag</publisher><subject>Adrenergic Agents - toxicity ; Animals ; Animals, Newborn ; Apomorphine - pharmacology ; Biomedical and Life Sciences ; Biomedicine ; Brain - drug effects ; Brain - metabolism ; Brain - pathology ; Cell Biology ; Disease Models, Animal ; Dopamine - metabolism ; Dopamine Agonists - pharmacology ; Dose-Response Relationship, Drug ; Exploratory Behavior - drug effects ; Histamine - metabolism ; Histamine Antagonists - pharmacology ; Locomotion - drug effects ; Locomotion - physiology ; Male ; Mouth Abnormalities - chemically induced ; Neurobiology ; Neurochemistry ; Neurology ; Neurosciences ; Oxidopamine - toxicity ; Parkinson Disease - etiology ; Parkinson Disease - metabolism ; Parkinson Disease - pathology ; Pharmacology/Toxicology ; Rats ; Rats, Wistar</subject><ispartof>Neurotoxicity research, 2009-04, Vol.15 (3), p.246-251</ispartof><rights>Springer Science+Business Media, LLC 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-47d5da267e5ece1413c31b08b8273fc747c82290fa2e5ea39bf2cbae4db9c2773</citedby><cites>FETCH-LOGICAL-c374t-47d5da267e5ece1413c31b08b8273fc747c82290fa2e5ea39bf2cbae4db9c2773</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12640-009-9025-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12640-009-9025-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19384597$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nowak, Przemysław</creatorcontrib><creatorcontrib>Noras, Łukasz</creatorcontrib><creatorcontrib>Jochem, Jerzy</creatorcontrib><creatorcontrib>Szkilnik, Ryszard</creatorcontrib><creatorcontrib>Brus, Halina</creatorcontrib><creatorcontrib>Körőssy, Eva</creatorcontrib><creatorcontrib>Drab, Jacek</creatorcontrib><creatorcontrib>Kostrzewa, Richard M.</creatorcontrib><creatorcontrib>Brus, Ryszard</creatorcontrib><title>Histaminergic Activity in a Rodent Model of Parkinson’s Disease</title><title>Neurotoxicity research</title><addtitle>Neurotox Res</addtitle><addtitle>Neurotox Res</addtitle><description>Rats lesioned shortly after birth with 6-OHDA have been proposed to be a near-ideal model of severe Parkinson’s disease, because of non-lethality of the procedure, near-total destruction of nigrostriatal dopaminergic fibers, and near-total dopamine (DA) denervation of striatum. There are scarce data that in Parkinson’s disease, activity of the central histaminergic system is increased. Therefore, the aim of this study was to determine histamine content in the brain and the effect of histamine receptor antagonists on behavior of adult rats. At 3 days after birth, Wistar rats were pretreated with desipramine (20.0 mg/kg
ip
) 1 h before bilateral
icv
administration of the catecholaminergic neurotoxin 6-OHDA (67 μg base, on each side) or saline-ascorbic acid (0.1%) vehicle (control). At 8 weeks levels of DA and its metabolites
l
-3,4-dihydroxyphenylalanine (DOPAC) and homovanillic acid (HVA) were estimated in the striatum and frontal cortex by HPCL/ED technique. In the hypothalamus, hippocampus, frontal cortex, and medulla oblongata, the level of histamine was analyzed by immunoenzymatic method. Behavioral observations (locomotion, exploratory-, oral-, and stereotyped-activity) were additionally made on control and 6-OHDA neonatally lesioned rats. Effects of DA receptor agonists (SKF 38393, apomorphine) and histamine receptor antagonists (e.g., S(+)chlorpheniramine, H
1
; cimetidine, H
2
; thioperamide, H
3
agonist) were determined. We confirmed that 6-OHDA significantly reduced contents of DA and its metabolites in the brain in adulthood. Histamine content was significantly increased in the hypothalamus, hipocampus, and medulla oblongata. Moreover, in 6-OHDA-lesioned rats behavioral response was altered mainly by thioperamide (H
3
antagonist). These findings indicate that histamine and the central histaminergic system are altered in the brain of rats lesioned to model Parkinson’s disease, and that histaminergic neurons exert a modulating role in Parkinsonian 6-OHDA-lesioned rats.</description><subject>Adrenergic Agents - toxicity</subject><subject>Animals</subject><subject>Animals, Newborn</subject><subject>Apomorphine - pharmacology</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Brain - pathology</subject><subject>Cell Biology</subject><subject>Disease Models, Animal</subject><subject>Dopamine - metabolism</subject><subject>Dopamine Agonists - pharmacology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Exploratory Behavior - drug effects</subject><subject>Histamine - metabolism</subject><subject>Histamine Antagonists - pharmacology</subject><subject>Locomotion - drug effects</subject><subject>Locomotion - physiology</subject><subject>Male</subject><subject>Mouth Abnormalities - chemically induced</subject><subject>Neurobiology</subject><subject>Neurochemistry</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Oxidopamine - toxicity</subject><subject>Parkinson Disease - etiology</subject><subject>Parkinson Disease - metabolism</subject><subject>Parkinson Disease - pathology</subject><subject>Pharmacology/Toxicology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><issn>1029-8428</issn><issn>1476-3524</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKAzEUhoMotlYfwI1k5S6a20wmy1IvFSqK6DpkMpmSOs3UZEboztfw9XwSU6bgztU5cL7_h_MBcE7wFcFYXEdCc44RxhJJTDNEDsCYcJEjllF-mHZMJSo4LUbgJMYVxpRkuTgGIyJZwTMpxmA6d7HTa-dtWDoDp6Zzn67bQuehhi9tZX0HH9NoYFvDZx3enY-t__n6jvDGRaujPQVHtW6iPdvPCXi7u32dzdHi6f5hNl0gwwTvEBdVVmmaC5tZYwknzDBS4qIsqGC1EVyYglKJa00ToZksa2pKbXlVSkOFYBNwOfRuQvvR29iptYvGNo32tu2jopgImjOZQDKAJrQxBlurTXBrHbaKYLXzpgZvKnlTO2-KpMzFvrwv17b6S-xFJYAOQEwnv7RBrdo--PTwP62_NU945w</recordid><startdate>20090401</startdate><enddate>20090401</enddate><creator>Nowak, Przemysław</creator><creator>Noras, Łukasz</creator><creator>Jochem, Jerzy</creator><creator>Szkilnik, Ryszard</creator><creator>Brus, Halina</creator><creator>Körőssy, Eva</creator><creator>Drab, Jacek</creator><creator>Kostrzewa, Richard M.</creator><creator>Brus, Ryszard</creator><general>Springer-Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>20090401</creationdate><title>Histaminergic Activity in a Rodent Model of Parkinson’s Disease</title><author>Nowak, Przemysław ; Noras, Łukasz ; Jochem, Jerzy ; Szkilnik, Ryszard ; Brus, Halina ; Körőssy, Eva ; Drab, Jacek ; Kostrzewa, Richard M. ; Brus, Ryszard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-47d5da267e5ece1413c31b08b8273fc747c82290fa2e5ea39bf2cbae4db9c2773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adrenergic Agents - toxicity</topic><topic>Animals</topic><topic>Animals, Newborn</topic><topic>Apomorphine - pharmacology</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Brain - pathology</topic><topic>Cell Biology</topic><topic>Disease Models, Animal</topic><topic>Dopamine - metabolism</topic><topic>Dopamine Agonists - pharmacology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Exploratory Behavior - drug effects</topic><topic>Histamine - metabolism</topic><topic>Histamine Antagonists - pharmacology</topic><topic>Locomotion - drug effects</topic><topic>Locomotion - physiology</topic><topic>Male</topic><topic>Mouth Abnormalities - chemically induced</topic><topic>Neurobiology</topic><topic>Neurochemistry</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Oxidopamine - toxicity</topic><topic>Parkinson Disease - etiology</topic><topic>Parkinson Disease - metabolism</topic><topic>Parkinson Disease - pathology</topic><topic>Pharmacology/Toxicology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nowak, Przemysław</creatorcontrib><creatorcontrib>Noras, Łukasz</creatorcontrib><creatorcontrib>Jochem, Jerzy</creatorcontrib><creatorcontrib>Szkilnik, Ryszard</creatorcontrib><creatorcontrib>Brus, Halina</creatorcontrib><creatorcontrib>Körőssy, Eva</creatorcontrib><creatorcontrib>Drab, Jacek</creatorcontrib><creatorcontrib>Kostrzewa, Richard M.</creatorcontrib><creatorcontrib>Brus, Ryszard</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Neurotoxicity research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nowak, Przemysław</au><au>Noras, Łukasz</au><au>Jochem, Jerzy</au><au>Szkilnik, Ryszard</au><au>Brus, Halina</au><au>Körőssy, Eva</au><au>Drab, Jacek</au><au>Kostrzewa, Richard M.</au><au>Brus, Ryszard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Histaminergic Activity in a Rodent Model of Parkinson’s Disease</atitle><jtitle>Neurotoxicity research</jtitle><stitle>Neurotox Res</stitle><addtitle>Neurotox Res</addtitle><date>2009-04-01</date><risdate>2009</risdate><volume>15</volume><issue>3</issue><spage>246</spage><epage>251</epage><pages>246-251</pages><issn>1029-8428</issn><eissn>1476-3524</eissn><abstract>Rats lesioned shortly after birth with 6-OHDA have been proposed to be a near-ideal model of severe Parkinson’s disease, because of non-lethality of the procedure, near-total destruction of nigrostriatal dopaminergic fibers, and near-total dopamine (DA) denervation of striatum. There are scarce data that in Parkinson’s disease, activity of the central histaminergic system is increased. Therefore, the aim of this study was to determine histamine content in the brain and the effect of histamine receptor antagonists on behavior of adult rats. At 3 days after birth, Wistar rats were pretreated with desipramine (20.0 mg/kg
ip
) 1 h before bilateral
icv
administration of the catecholaminergic neurotoxin 6-OHDA (67 μg base, on each side) or saline-ascorbic acid (0.1%) vehicle (control). At 8 weeks levels of DA and its metabolites
l
-3,4-dihydroxyphenylalanine (DOPAC) and homovanillic acid (HVA) were estimated in the striatum and frontal cortex by HPCL/ED technique. In the hypothalamus, hippocampus, frontal cortex, and medulla oblongata, the level of histamine was analyzed by immunoenzymatic method. Behavioral observations (locomotion, exploratory-, oral-, and stereotyped-activity) were additionally made on control and 6-OHDA neonatally lesioned rats. Effects of DA receptor agonists (SKF 38393, apomorphine) and histamine receptor antagonists (e.g., S(+)chlorpheniramine, H
1
; cimetidine, H
2
; thioperamide, H
3
agonist) were determined. We confirmed that 6-OHDA significantly reduced contents of DA and its metabolites in the brain in adulthood. Histamine content was significantly increased in the hypothalamus, hipocampus, and medulla oblongata. Moreover, in 6-OHDA-lesioned rats behavioral response was altered mainly by thioperamide (H
3
antagonist). These findings indicate that histamine and the central histaminergic system are altered in the brain of rats lesioned to model Parkinson’s disease, and that histaminergic neurons exert a modulating role in Parkinsonian 6-OHDA-lesioned rats.</abstract><cop>New York</cop><pub>Springer-Verlag</pub><pmid>19384597</pmid><doi>10.1007/s12640-009-9025-1</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1029-8428 |
| ispartof | Neurotoxicity research, 2009-04, Vol.15 (3), p.246-251 |
| issn | 1029-8428 1476-3524 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20172639 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adrenergic Agents - toxicity Animals Animals, Newborn Apomorphine - pharmacology Biomedical and Life Sciences Biomedicine Brain - drug effects Brain - metabolism Brain - pathology Cell Biology Disease Models, Animal Dopamine - metabolism Dopamine Agonists - pharmacology Dose-Response Relationship, Drug Exploratory Behavior - drug effects Histamine - metabolism Histamine Antagonists - pharmacology Locomotion - drug effects Locomotion - physiology Male Mouth Abnormalities - chemically induced Neurobiology Neurochemistry Neurology Neurosciences Oxidopamine - toxicity Parkinson Disease - etiology Parkinson Disease - metabolism Parkinson Disease - pathology Pharmacology/Toxicology Rats Rats, Wistar |
| title | Histaminergic Activity in a Rodent Model of Parkinson’s Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T14%3A15%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Histaminergic%20Activity%20in%20a%20Rodent%20Model%20of%20Parkinson%E2%80%99s%20Disease&rft.jtitle=Neurotoxicity%20research&rft.au=Nowak,%20Przemys%C5%82aw&rft.date=2009-04-01&rft.volume=15&rft.issue=3&rft.spage=246&rft.epage=251&rft.pages=246-251&rft.issn=1029-8428&rft.eissn=1476-3524&rft_id=info:doi/10.1007/s12640-009-9025-1&rft_dat=%3Cproquest_cross%3E20172639%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20172639&rft_id=info:pmid/19384597&rfr_iscdi=true |